We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

183 hedge funds and large institutions have $980M invested in AbCellera Biologics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

504% more call options, than puts

Call options by funds: $13.3M | Put options by funds: $2.2M

15% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 55

0.47% more ownership

Funds ownership: 44.73% → 45.19% (+0.47%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

10% less funds holding

Funds holding: 203 → 183 (-20)

24% less capital invested

Capital invested by funds: $1.3B → $980M (-$316M)

45% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 40

Holders
183
Holders Change
-20
Holders Change %
-9.85%
% of All Funds
2.92%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
22
Increased
63
Reduced
55
Closed
40
Calls
$13.3M
Puts
$2.2M
Net Calls
+$11.1M
Net Calls Change
-$189K

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$8.44M
2
Millennium Management
Millennium Management
New York
+$7.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$6.26M
4
HF
HRT Financial
New York
+$5.05M
5
CS
Credit Suisse
Switzerland
+$4.61M

Top Sellers

1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$8.89M
2
TC
TwinBeech Capital
New York
-$5.31M
3
N
Nuveen
North Carolina
-$3.58M
4
Man Group
Man Group
United Kingdom
-$3.09M
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
51
Victory Capital Management
Texas
$1.32M +$1.46M +160,975 +1,197%
GC
52
Gruss & Co
Florida
$1.26M -$798K -87,900 -34%
Ensign Peak Advisors
53
Ensign Peak Advisors
Utah
$1.25M – – –
Bank of America
54
Bank of America
North Carolina
$1.25M +$617K +67,932 +70%
Squarepoint
55
Squarepoint
New York
$1.19M -$355K -39,145 -20%
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$1.16M -$116K -12,770 -8%
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$1.11M -$313K -34,455 -19%
Wells Fargo
58
Wells Fargo
California
$1.08M +$534K +58,806 +70%
DA
59
Duality Advisers
Florida
$953K +$1.15M +126,388 New
Voloridge Investment Management
60
Voloridge Investment Management
Florida
$944K +$1.14M +125,244 New
GAM
61
Gotham Asset Management
New York
$929K +$65K +7,162 +6%
Macquarie Group
62
Macquarie Group
Australia
$900K – – –
PAMP
63
Polar Asset Management Partners
Ontario, Canada
$888K – – –
AI
64
ArchPoint Investors
Florida
$868K – – –
MIM
65
MetLife Investment Management
New Jersey
$827K – – –
SO
66
STRS Ohio
Ohio
$799K +$114K +12,600 +13%
SAM
67
Stansberry Asset Management
Texas
$766K +$12.4K +1,361 +1%
AIG
68
American International Group
New York
$754K +$18.1K +1,989 +2%
Mirae Asset Global Investments
69
Mirae Asset Global Investments
South Korea
$743K -$1.31K -144 -0.1%
Qube Research & Technologies (QRT)
70
Qube Research & Technologies (QRT)
United Kingdom
$721K -$1.48M -162,896 -63%
Invesco
71
Invesco
Georgia
$718K +$155K +17,017 +22%
EMG
72
ETF Managers Group
New Jersey
$713K +$858K +94,496 New
JF
73
Jump Financial
Illinois
$694K +$835K +92,000 New
DA
74
Denali Advisors
California
$661K +$795K +87,600 New
QT
75
Quantbot Technologies
New York
$653K +$630K +69,417 +403%
1 2
3
4 5

ABCL Hedge Fund Activity: Q1 2023 in Review

183 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2023, worth a combined $980M — down 24% from $1.3B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of ABCL and 22 opened new positions — a net loss of 18 holders — while 55 trimmed existing stakes and 63 added.

The largest buyer was Norges Bank, adding an estimated $8.44M. The largest seller was D.E. Shaw & Co, cutting an estimated $8.89M.

  • 183 institutional investors held AbCellera Biologics (ABCL) as of Q1 2023, down from 203 in Q4 2022.
  • Funds reported $980M of AbCellera Biologics stock for Q1 2023, down 24% quarter-over-quarter.
  • 22 funds opened new AbCellera Biologics positions in Q1 2023 and 40 closed out, a net change of -18 holders.
  • The largest AbCellera Biologics buyer in Q1 2023 was Norges Bank, an estimated $8.44M added.
  • The largest AbCellera Biologics seller in Q1 2023 was D.E. Shaw & Co, an estimated $8.89M sold.

Based on aggregated 13F filings for Q1 2023.